---
title: "AtriCure, Inc. (ATRC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATRC.US.md"
symbol: "ATRC.US"
name: "AtriCure, Inc."
industry: "Health Care Equipment"
datetime: "2026-03-13T12:50:37.091Z"
locales:
  - [en](https://longbridge.com/en/quote/ATRC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATRC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATRC.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ATRC.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ATRC.US.md)


# AtriCure, Inc. (ATRC.US)

## Company Overview

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.atricure.com](https://www.atricure.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:17.000Z

**Overall: B (0.38)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 14.88% |  |
| Net Profit YoY | 74.39% |  |
| P/B Ratio | 2.99 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1471135426.04 |  |
| Revenue | 534528000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.40% | D |
| Profit Margin | -2.14% | D |
| Gross Margin | 74.98% | A |
| Revenue YoY | 14.88% | B |
| Net Profit YoY | 74.39% | A |
| Total Assets YoY | 7.36% | B |
| Net Assets YoY | 6.72% | B |
| Cash Flow Margin | -4669.18% | E |
| OCF YoY | 14.88% | B |
| Turnover | 0.85 | B |
| Gearing Ratio | 24.80% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AtriCure, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "14.88%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "74.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.99",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1471135426.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "534528000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.40%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-2.14%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "74.98%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "14.88%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "74.39%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.36%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.72%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-4669.18%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "14.88%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.85",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.80%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -128.51 | 170/188 | - | - | - |
| PB | 2.99 | 73/188 | 3.96 | 3.70 | 3.41 |
| PS (TTM) | 2.75 | 69/188 | 3.68 | 3.48 | 3.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Abbott Laboratories (ABT.US) | B | C | C | C | C | B |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | B | B | C | B | B |
| 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-11T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 44% |
| Overweight | 3 | 33% |
| Hold | 2 | 22% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 29.54 |
| Highest Target | 55.00 |
| Lowest Target | 36.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATRC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATRC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATRC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATRC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**